REG - Genflow Biosciences - International Patent Publication

Genflow BiosciencesAnnouncement

13/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM9012Za&default-theme=true

RNS Number : 9012Z  Genflow Biosciences PLC  13 April 2026

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

13 April 2026

 

Genflow Biosciences Plc

International Patent Publication Expands Protection for SIRT6-Based Muscular
Disease Program

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or the "Company"),
a European-based biotechnology company focused on the development of gene
therapies for age-related diseases, is pleased to announce the international
publication of its Patent Cooperation Treaty (PCT) application, WO 2026/062177
A1, entitled "Variants of Sirtuin 6 for the Treatment of Muscular Diseases."

 

The published PCT application relates to variants of SIRT6 for the prevention
and treatment of muscular diseases, with particular focus on frailty syndrome
and sarcopenia. The application describes compositions and methods involving
SIRT6 variants, including nucleic acids, polypeptides, vectors and
pharmaceutical compositions intended for use in muscular disease settings
associated with loss of muscle mass and altered endocrine function of the
muscle.

 

This international publication represents an important milestone in Genflow's
intellectual property strategy and broadens the potential protection
surrounding the Company's SIRT6 platform beyond longevity and metabolic
applications. By advancing patent coverage into muscular diseases, Genflow is
further strengthening the proprietary foundation of its platform while opening
additional potential therapeutic pathways for development and partnering.

 

Strategic Significance

The publication enhances the visibility and scope of Genflow's IP estate at an
international level. It supports the Company's strategy of building layered
protection around the therapeutic use of SIRT6 variants across multiple
age-related indications.  The PCT publication also preserves Genflow's
ability to pursue patent protection across multiple jurisdictions, supporting
development flexibility and potential discussions with pharmaceutical and
biotech partners. Taken together, this publication reinforces the depth of the
Company's scientific platform and the continued expansion of its intellectual
property backbone.

 

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented:
"The international publication of this patent application marks another
important step in the expansion of Genflow's intellectual property portfolio.
By extending our SIRT6 platform into muscular diseases such as frailty and
sarcopenia, we are continuing to build strategic protection around areas of
high unmet need and significant relevance to healthy ageing. This publication
further strengthens our position as we advance the development and potential
partnering of our gene therapy platform."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32 477495 881       +1 475 477 9401
                      Jonathan@Harbor-Access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies for age-related diseases, with the goal
of promoting longer and healthier lives while mitigating the financial,
emotional, and social impacts of a fast-growing aging global population.
Genflow's lead compound, GF-1002, works through the delivery of a centenarian
variant of the SIRT6 gene which has yielded promising preclinical results.
Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian
gene therapy in aged dogs began in March 2025. Other programs include a
clinical trial that will explore the potential benefits of GF-1002 in treating
MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent
chronic liver disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

 

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

 

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

 

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKCBQKBKBKQK



            Copyright 2019 Regulatory News Service, all rights reserved